CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Euroimmun, headquartered in Luebeck, Germany, has developed a system of comprehensive tests available for the serological detection and differentiation of Zika virus infections.
The Euroimmun Anti-Zika Virus ELISA and indirect immunofluorescence test formats allow for detection of specific antibodies (IgM and IgG) in the blood of those who may be infected. These tests provide a longer window for detection than the currently available qPCR-based assay alone, making them useful for disease surveillance. The tests can be used to diagnose patients with acute symptoms and to manage asymptomatic cases that fit a risk profile, particularly pregnant women. The highly specific viral antigen used in the ELISA assay eliminates cross reactivity with other flavivirus antibodies, ensuring differentiation from diseases such as dengue fever. These fully automated antibody detection test kits are suitable for rapid screening of large patient volumes. The CE-marked kits are for research use only.
Euroimmun, 973-656-1000